Recent activity in the market suggests a mixed outlook for insurance giant
MetLife (MET). The recent drop in share price has prompted analysis of MET's valuation with some analysts suggesting the price weakness might represent a good buying opportunity. MetLife has undergone a variety of share manipulations including
several large purchases, price target adjustments, and stock awards given to board directors. It has even engaged in share buybacks amid its decline in Q3 earnings results.
Consequently, MetLife's board has been expanded, and it has appointed two experienced leaders. MetLife has also issued $1 billion in subordinated debentures to increase its capital. Analysts have provided diverging views on its valuation and investment narrative, considering
global growth and strategic opportunities. MET reported a miss in Q4 and Q3 sales expectations, yet its Q4 earnings were bolstered due to the performance of its Group Benefits and RIS units.
The introduction of the New MIM segment and Capital Returns could potentially reshape MetLife's core narrative. Finally, MetLife announced dividend declarations on preferred stocks and completed a variable annuity risk transfer transaction of $10 billion.
Metlife MET News Analytics from Tue, 29 Jul 2025 07:00:00 GMT to Sat, 28 Feb 2026 11:10:45 GMT -
